{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:31:38Z","timestamp":1785259898035,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-023-00893-9","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T12:01:30Z","timestamp":1691582490000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Coincidence of cutaneous blastic plasmacytoid dendritic cell neoplasm and myelodysplastic syndrome derived from clonal hematopoiesis"],"prefix":"10.1038","volume":"13","author":[{"given":"Tomohiko","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0472-6680","authenticated-orcid":false,"given":"Nobuhiro","family":"Hiramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukimasa","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Nishikubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Maruoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Nannya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7778-5374","authenticated-orcid":false,"given":"Seishi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,9]]},"reference":[{"key":"893_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720\u201348.","journal-title":"Leukemia"},{"key":"893_CR2","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1182\/bloodadvances.2020003359","volume":"5","author":"F Renosi","year":"2021","unstructured":"Renosi F, Roggy A, Giguelay A, Soret L, Viailly PJ, Cheok M, et al. Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis. Blood Adv. 2021;5:1540\u201351.","journal-title":"Blood Adv"},{"key":"893_CR3","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2159-8290.CD-20-1513","volume":"12","author":"K Togami","year":"2022","unstructured":"Togami K, Chung SS, Madan V, Booth CAG, Kenyon CM, Cabal-Hierro L, et al. Sex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis. Cancer Discov. 2022;12:522\u201341.","journal-title":"Cancer Discov"},{"key":"893_CR4","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/leu.2013.283","volume":"28","author":"J Menezes","year":"2014","unstructured":"Menezes J, Acquadro F, Wiseman M, G\u00f3mez-L\u00f3pez G, Salgado RN, Talavera-Casa\u00f1as JG, et al. Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2014;28:823\u20139.","journal-title":"Leukemia"},{"key":"893_CR5","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1182\/blood-2019-132185","volume":"134","author":"N Pemmaraju","year":"2019","unstructured":"Pemmaraju N, Kantarjian HM, Khoury JD, Loghavi S, O'Brien S, Cortes JE, et al. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) commonly presents in the setting of prior or concomitant hematologic malignancies (PCHM): patient characteristics and outcomes in the rapidly evolving modern targeted therapy era. Blood. 2019;134:2723\u20132723.","journal-title":"Blood"},{"key":"893_CR6","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1038\/leu.2017.38","volume":"31","author":"L Brunetti","year":"2017","unstructured":"Brunetti L, Di Battista V, Venanzi A, Schiavoni G, Martelli MP, Ascani S, et al. Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin. Leukemia. 2017;31:1238\u201340.","journal-title":"Leukemia"},{"key":"893_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0120-5","volume":"8","author":"MM Patnaik","year":"2018","unstructured":"Patnaik MM, Lasho T, Howard M, Finke C, Ketterling RL, Al-Kali A, et al. Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms. Blood cancer J. 2018;8:82.","journal-title":"Blood cancer J"},{"key":"893_CR8","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1038\/s41375-021-01228-y","volume":"35","author":"K Batta","year":"2021","unstructured":"Batta K, Bossenbroek HM, Pemmaraju N, Wilks DP, Chasty R, Dennis M, et al. Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin. Leukemia. 2021;35:3299\u2013303.","journal-title":"Leukemia"},{"key":"893_CR9","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/s41375-022-01538-9","volume":"36","author":"M Khanlari","year":"2022","unstructured":"Khanlari M, Yin CC, Takahashi K, Lachowiez C, Tang G, Loghavi S, et al. Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. Leukemia. 2022;36:1343\u201350.","journal-title":"Leukemia"},{"key":"893_CR10","doi-asserted-by":"publisher","first-page":"E31","DOI":"10.1002\/ajh.25675","volume":"95","author":"M Li","year":"2020","unstructured":"Li M, Shah M, Binder M, Lasho T, Carr R, Mangaonkar A, et al. Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of TET2 and ZRSR2 mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving CDK2NA\/2NB and MTAP. Am J Hematol. 2020;95:E31\u2013e34.","journal-title":"Am J Hematol"},{"key":"893_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40164-018-0117-6","volume":"7","author":"K Chamoun","year":"2018","unstructured":"Chamoun K, Loghavi S, Pemmaraju N, Konopleva M, Kroll M, Nguyen-Cao M, et al. Early detection of transformation to BPDCN in a patient with MDS. Exp Hematol Oncol. 2018;7:26.","journal-title":"Exp Hematol Oncol"},{"key":"893_CR12","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/jha2.525","volume":"3","author":"S El Hussein","year":"2022","unstructured":"El Hussein S, Yabe M, Wang W, Pemmaraju N, Loghavi S, Jelloul FZ, et al. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) arising in the setting of polycythemia vera (PV): An illustration of the emerging role of flow cytometry analysis in monitoring progression of myeloproliferative neoplasms. EJHaem. 2022;3:954\u20137.","journal-title":"EJHaem"},{"key":"893_CR13","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1002\/ajh.23567","volume":"88","author":"K Alayed","year":"2013","unstructured":"Alayed K, Patel KP, Konoplev S, Singh RR, Routbort MJ, Reddy N, et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013;88:1055\u201361.","journal-title":"Am J Hematol"},{"key":"893_CR14","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1182\/bloodadvances.2022007879","volume":"7","author":"H Beird","year":"2023","unstructured":"Beird H, Yin CC, Khoury JD, Pierce S, Abbas HA, Zhao L, et al. TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm. Blood Adv. 2023;7:2000\u20133.","journal-title":"Blood Adv"},{"key":"893_CR15","first-page":"257","volume":"21","author":"N Pemmaraju","year":"2023","unstructured":"Pemmaraju N, Kantarjian H. Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023. Clin Adv Hematol Oncol. 2023;21:257\u201364.","journal-title":"Clin Adv Hematol Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00893-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00893-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00893-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T09:03:46Z","timestamp":1700298226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00893-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,9]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["893"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00893-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,9]]},"assertion":[{"value":"14 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"119"}}